Spots Global Cancer Trial Database for pm01183
Every month we try and update this database with for pm01183 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | NCT01314599 | Acute Leukemia | PM01183 1 mg Po... | 18 Years - | PharmaMar | |
| Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks | NCT01405391 | Major Advanced ... | PM01183 | 18 Years - | PharmaMar | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | NCT01525589 | Breast Cancer | PM01183 | 18 Years - 75 Years | PharmaMar | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | NCT01525589 | Breast Cancer | PM01183 | 18 Years - 75 Years | PharmaMar | |
| Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | NCT01314599 | Acute Leukemia | PM01183 1 mg Po... | 18 Years - | PharmaMar | |
| A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | NCT02448537 | Metastatic Sarc... | PM01183 Doxorubicin Gemcitabine | 18 Years - 75 Years | Massachusetts General Hospital | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks | NCT01405391 | Major Advanced ... | PM01183 | 18 Years - | PharmaMar | |
| Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors | NCT01970553 | Specific Advanc... | lurbinectedin (... Gemcitabine | 18 Years - 75 Years | PharmaMar | |
| Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors | NCT00877474 | ADVANCED SOLID ... | PM01183 | 18 Years - | PharmaMar |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
